NSAA-engineered peptidomimetics act as pan-variant RBD inhibitors, resisting antigenic drift while preserving host-binding specificity. This computational-quantum hybrid strategy offers a blueprint for resilient antiviral therapeutics against evolving pathogens.
Losery et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: